Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Section 6 of 6

References

119 sources

  1. ADARx Pharmaceuticals (opens in a new tab)
  2. ADARx Pharmaceuticals (2023) (opens in a new tab)
  3. ADARx Pharmaceuticals (2025) (opens in a new tab)
  4. ADARx Pharmaceuticals Fast Track designation announcement (2026) (opens in a new tab)
  5. ADARx Pharmaceuticals Form 10-Q (2026) (opens in a new tab)
  6. ADARx Pharmaceuticals onvuzosiran data announcement (2026) (opens in a new tab)
  7. ADARx Pharmaceuticals presentation (2026) (opens in a new tab)
  8. ADARx Pharmaceuticals prospectus (2026) (opens in a new tab)
  9. ADARx Pharmaceuticals third quarter 2026 results announcement (2026) (opens in a new tab)
  10. Argo Biopharma (2026) (opens in a new tab)
  11. Arora et al. (2023) (opens in a new tab)
  12. Banerji et al. (2018) (opens in a new tab)
  13. Beard et al. (2022) (opens in a new tab)
  14. Betschel et al. (2026) (opens in a new tab)
  15. BioCryst Pharmaceuticals (2026) (opens in a new tab)
  16. BioCryst Pharmaceuticals Colorado WAC disclosure (2026) (opens in a new tab)
  17. Bork et al. (2006) (opens in a new tab)
  18. Bork et al. (2012) (opens in a new tab)
  19. Broderick et al. (2025) (opens in a new tab)
  20. Busse et al. (2021) (opens in a new tab)
  21. Busse et al. (2026) (opens in a new tab)
  22. Caballero et al. (2026) (opens in a new tab)
  23. Cancian et al. (2026a) (opens in a new tab)
  24. Cancian et al. (2026b) (opens in a new tab)
  25. Castaldo et al. (2021) (opens in a new tab)
  26. Castaldo et al. (2025) (opens in a new tab)
  27. Christiansen et al. (2023) (opens in a new tab)
  28. ClinicalTrials.gov NCT05139810 (opens in a new tab)
  29. ClinicalTrials.gov NCT05392114 (opens in a new tab)
  30. ClinicalTrials.gov NCT05691361 (opens in a new tab)
  31. ClinicalTrials.gov NCT06960213 (opens in a new tab)
  32. ClinicalTrials.gov NCT07428499 (opens in a new tab)
  33. CMS Clinical Laboratory Fee Schedule (2026) (opens in a new tab)
  34. CMS Medicare Part B payment limit file (2026) (opens in a new tab)
  35. CMS Medicare Part D Spending by Drug (2026) (opens in a new tab)
  36. Craig et al. (2023) (opens in a new tab)
  37. Craig et al. (2026) (opens in a new tab)
  38. CSL (2023) (opens in a new tab)
  39. CSL Behring (2022) (opens in a new tab)
  40. CSL Behring (2026) (opens in a new tab)
  41. Danielsson et al. (2025) (opens in a new tab)
  42. Datta et al. (2026) (opens in a new tab)
  43. Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026) (opens in a new tab)
  44. EU Clinical Trials Register 2013-000916-10 (opens in a new tab)
  45. Farkas et al. (2026) (opens in a new tab)
  46. FDA (2018) (opens in a new tab)
  47. FDA (2020) (opens in a new tab)
  48. FDA (2022) (opens in a new tab)
  49. FDA ANDEMBRY prescribing information (2025) (opens in a new tab)
  50. FDA DAWNZERA prescribing information (2025) (opens in a new tab)
  51. FDA Drug Trials Snapshot ANDEMBRY (2025) (opens in a new tab)
  52. FDA Drug Trials Snapshot DAWNZERA (opens in a new tab)
  53. FDA Drug Trials Snapshot EKTERLY (opens in a new tab)
  54. FDA ORLADEYO prescribing information (2026) (opens in a new tab)
  55. FDA TAKHZYRO prescribing information (2026) (opens in a new tab)
  56. Feld et al. (2026) (opens in a new tab)
  57. Fisch et al. (2025) (opens in a new tab)
  58. Grover et al. (2022) (opens in a new tab)
  59. Guan et al. (2024) (opens in a new tab)
  60. Health Research Authority (2025) (opens in a new tab)
  61. Health Research Authority (2026) (opens in a new tab)
  62. Henao et al. (2016) (opens in a new tab)
  63. ICER (2021) (opens in a new tab)
  64. ICER final evidence report (2018) (opens in a new tab)
  65. Intellia Therapeutics (2025) (opens in a new tab)
  66. Intellia Therapeutics (2026) (opens in a new tab)
  67. Intellia Therapeutics AAAAI poster (2026) (opens in a new tab)
  68. Intellia Therapeutics investor presentation (2024) (opens in a new tab)
  69. Ionis Pharmaceuticals protocol and statistical analysis plan (2023) (opens in a new tab)
  70. KalVista Pharmaceuticals Colorado WAC disclosure (2026) (opens in a new tab)
  71. Khalid and Hitch (2025) (opens in a new tab)
  72. Kiani-Alikhan et al. (2024) (opens in a new tab)
  73. Kim et al. (2014) (opens in a new tab)
  74. Kutrieb et al. (2026) (opens in a new tab)
  75. Li et al. (2026) (opens in a new tab)
  76. Longhurst et al. (2017) (opens in a new tab)
  77. Lumry et al. (2010) (opens in a new tab)
  78. Lumry et al. (2018) (opens in a new tab)
  79. Lumry et al. (2021) (opens in a new tab)
  80. Lumry et al. (2026) (opens in a new tab)
  81. Maurer et al. (2022) (opens in a new tab)
  82. MedlinePlus (opens in a new tab)
  83. Minafra et al. (2022a) (opens in a new tab)
  84. Minafra et al. (2022b) (opens in a new tab)
  85. MO HealthNet Andembry fact blast (2025) (opens in a new tab)
  86. MO HealthNet Dawnzera fact blast (2025) (opens in a new tab)
  87. Murai et al. (2026) (opens in a new tab)
  88. NICE (2026) (opens in a new tab)
  89. Olson et al. (2026) (opens in a new tab)
  90. Pharvaris (2026) (opens in a new tab)
  91. Princic et al. (2025) (opens in a new tab)
  92. Riedl et al. (2024a) (opens in a new tab)
  93. Riedl et al. (2024b) (opens in a new tab)
  94. Riedl et al. (2025) (opens in a new tab)
  95. Riedl et al. (2026a) (opens in a new tab)
  96. Riedl et al. (2026b) (opens in a new tab)
  97. Sandberg et al. (2024) (opens in a new tab)
  98. Santé.fr (2026) (opens in a new tab)
  99. Shah et al. (2023) (opens in a new tab)
  100. Singh et al. (2025) (opens in a new tab)
  101. Smith et al. (2023) (opens in a new tab)
  102. Staubach et al. (2025) (opens in a new tab)
  103. Sundler Björkman et al. (2022) (opens in a new tab)
  104. Tachdjian et al. (2026) (opens in a new tab)
  105. Uminski et al. (2025) (opens in a new tab)
  106. US Hereditary Angioedema Association (opens in a new tab)
  107. Vanya et al. (2023) (opens in a new tab)
  108. Vázquez et al. (2026) (opens in a new tab)
  109. Villa et al. (2026) (opens in a new tab)
  110. Walsh et al. (2025) (opens in a new tab)
  111. Watt et al. (2023) (opens in a new tab)
  112. Watt et al. (2026) (opens in a new tab)
  113. Weller et al. (2016) (opens in a new tab)
  114. Weller et al. (2020) (opens in a new tab)
  115. Wilson et al. (2010) (opens in a new tab)
  116. Wong et al. (2025) (opens in a new tab)
  117. World Health Organization (2024) (opens in a new tab)
  118. Zuraw et al. (2021) (opens in a new tab)
  119. Zuraw et al. (2025) (opens in a new tab)